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SMethods: 2,621 patients underwent TAVR with the SAPIEN heart valve via TF
(N¼1521) or TA (N¼1100) delivery routes between April 2007 and January 2012.
The study was divided into 2 time domains for this analysis, 1st half (2007 – 2009)
and 2nd half (2010 – 2012). The Shapes of the learning curves were assessed using
a semi-parametric mixed effects model.
Results: Figure 1A details the outcomes of the technical performance variables. Using
the date of implant, there appeared to be a signiﬁcant downward trend in procedure
times (Figure 1B), ﬂuoroscopy times and contrast volume. (Figure 1C and D) The
improvement in these parameters was particularly striking in TF cases p < 0.005.Conclusions: Our results demonstrate that in the PARTNER trial there is an important
TAVR learning curve with signiﬁcant improvement in procedural and performance
variables over time. Although the differences in primary operator skill sets between
TA and TF approaches may explain some of the observed heterogeneity in learning
curves, a critical volume of cases appears necessary to become proﬁcient in the safe
performance of TAVR, particularly via the TF route.
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Background: Acute Kidney injury (AKI) after cardiac surgery is associated with
increased mortality, but very few data exist on the occurrence of AKI associated with
Transcatheter Aortic Valve Implantation (TAVI). The objective of this study was to
determine the incidence and prognosis of AKI after percutaneous implantation of the
CoreValve aortic prosthesis.
Methods: Between April-2008 and January-2011, 223 patients with severe aortic
stenosis were treated with the CoreValve prosthesis. The AKI was deﬁned according
to Valve set by the Academic Research Consortium, as the absolute increase in serum
creatinine 0.3 mg/dl at 72 hours a percutaneous procedure.
Results: AKI was identiﬁed in 37 patients (16.6%) and none required renal
replacement therapy. After implantation there was a slight improvement in renal
function, baseline serum creatinine decreased from 1.290.5 mg/dl to 1.22 mg/dl,
P¼0.023 and glomerular ﬁltration rate (GFR) increased from 49.622 to 5223,
P¼0.015. In patients with AKI, the mortality at 30 days was 13.5 % compared to 1.6%
of patients without AKI, P¼0.001 and late mortality after a mean of 16.711 months
was 18.8% in those patients with AKI compared to 8.2% in those without AKI,
P¼0.068. In the multivariate analysis AKI was an independent predictor of cumulative
total mortality (HR¼3.516, 95% CI from 1.098 to 11.255, P¼0.034).
Conclusions: Deterioration of renal function in patients undergoing TAVI with the
CoreValve prosthesis is a serious and frequent complication. The occurrence of AKI
was associated with increase early mortality and also was a predictor of worse
outcomes in the long-term follow-up.
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Background: Accurate sizing of the aortic annulus is an important premise for
successful Transcatheter aortic valve implantation (TAVI). Multislice computed
tomography (MSCT) may have advantages over other imaging modalities, but there is
uncertainty whether 1) measurements should be performed in systole or diastole and
2) if calculation of the effective annulus diameter should be based on area orB228 JACC Vol 62/18/Suppl B j October 27–Novemberperimeter. Aim of our study was to compare MSCT results with direct intraoperative
sizing of the annulus.
Methods: Conventional aortic valve replacement was performed in 25 patients who
were primarily screened for TAVI, but were deemed inappropriate for several reasons,
and the annulus was measured intraoperatively after decalciﬁcation using metric
sizers. All patients had undergone transesophageal echocardiography (TEE) and
MSCT for TAVI workup and effective annulus diameter was determined derived by
area (AsysA, AdiaA) and perimeter (AsysP, AdiaP) in systole and diastole, respec-
tively. Additionally, potential change of strategy for the different approaches
compared to intraoperative annulus sizing in case of TAVI using the Edwards Sapien
XT valve was simulated.
Results: Best agreement with direct operative sizing (intraop) was observed for
AsysA in the Bland-Altman analysis (mean difference between intraop vs. AsysA
-0.17 mm, limits of agreement -1.98 – 1.64; intraop vs. AdiaA 0.65 mm, limits of
agreement -1.56 to 2.86; intraop vs. AsysP -0.92 mm, limits of agreement -2.81 to
0.97 and intraop vs. AdiaP -0.29 mm, limits of agreement -2.85 to 2.27), TEE 1.5 mm,
limits of agreement -2.77 to 2.27). Least change of strategy would have occurred with
AsysA (20%), followed by AdiaP (28%), AdiaA (30%) and AsysP (40%).
Conclusions: Compared to surgical sizing area derived measurement in systole
represents the best approach for annulus determination with least strategy change.
Perimeter derived measurement in systole may lead to overestimation of the true
annulus size.
TCT-750
Positioning and Implantation of the Direct Flow Medical Transcatheter Heart
Valve without contrast media
Azeem Latib1, Giuseppe Bruschi2, Antonio Colombo3, Charles J. Davidson4,
Federico De Marco2, Silvio Klugmann2, Francesco Maisano5, Joachim Schofer6
1San Raffaele Scientiﬁc Institute, Milan, Italy, 2Niguarda Ca’ Granda Hospital,
Milan, Italy, 3EMO GVM Centro Cuore Columbus/San Raffaele Hospital, Milan,
Italy, 4Northwestern Memorial Hospital, Chicago, Illinois, 5San Raffaele Hospital,
Milan, Italy, 6Medicare center Prof Mathey, Prof Schofer, Hamburg University
Cardiovascular Center, Hamburg, Germany
Background: The 18F Direct Flow Medical (DFM) THV has conformable sealing
rings which minimizes aortic regurgitation and permits full hemodynamic assessment
of valve performance prior to permanent implantation.
Methods: The DISCOVER trial was a prospective, multicenter evaluation of 100
patients who underwent TAVI with the DFM THV. Within this study, 3 patients were
at risk for receiving contrast media: 2 due to severe CKD (eGFR < 30 mL/min/1.73
m2) and 1 due to a recent hyperthyroid reaction to contrast. The valve was positioned
under ﬂuoroscopic and transesophageal guidance without aortography during either
positioning or to conﬁrm the ﬁnal position. Valve positioning was based on the
optimal angiographic projection as calculated by the pre-procedural multi-slice CT
scan. Precise optimization of valve position was performed to minimize transvalve
gradient and aortic regurgitation. Prior to ﬁnal implantation, transvalve hemodynamics
were assessed invasively and by TEE.
Results: The average age was 81 years. The baseline logistic EuroSCORE were 15,
18 and 24. LVEF was 33, 40, and 62%. The post procedure mean gradients were 7,
10, 11 mmHg. The ﬁnal AVA by echo was 1.70, 1.40 and 1.68 cm2. Total aortic
regurgitation post procedure was none or trace in all 3 patients. Total positioning and
assessment of valve performance time was 4, 6, and 12 minutes, and total skin to skin
procedure time were 29, 47, and 64 minutes. A 25mm valve was used in all 3. There
was 100% freedom from all cause mortality at 30 days. VARC deﬁned device success
was 100% and patient safety freedom from events was 100%. One had a permanent
pacemaker due to AV block. Contrast was only used to conﬁrm successful percuta-
neous closure of the femoral access site. The total contrast dose was 5, 8, 12 cc.
Baseline eGFR and creatinine was 28, 22, 74 mL/mn/1.73 m2 and 2.35, 2.98, and 1.03
mg/dL, respectively. Renal function was unchanged post procedure: eGFR¼25, 35,
and 96 mL/mn/1.73 m2 and creatinine¼2.58, 1.99, and 1.03 mg/dL, respectively.
Conclusions: The DFM THV provides the ability to perform TAVI with minimal or
no contrast. The precise and predictable implantation technique can be performed with
ﬂuoro and echo guidance.
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Background: Severe AS is a leading cause of morbidity and mortality in elderly.A
proportion of patients is now considered for transcatheter aortic valve replacement
(TAVR).We i) performed a meta-analysis on the prevalence of AS in the elderly and
ii) systematically estimated the number of candidates for TAVR.
Methods: A systematic search was conducted in multiple databases and prevalence
rates of patients (>75 years) were pooled.A model was based on a second systematic1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment







Sliterature search of studies on decision making in AS.Monte Carlo simulations were
performed to estimate the number of TAVR candidates in 19 European countries and
North America.
Results: Data from 7 studies (n¼9,723 subjects) were used.The prevalence of all AS
in the elderly was 12.4%(95%CI:6.6-18.2%),and the prevalence of severe AS was
3.4% (95%CI:1.1-5.7%).Among elderly with severe AS,75.6% (95%CI:65.8-85.4%)
were symptomatic,and 40.5% (95%CI:35.8-45.1%) of these patients were not treated
surgically.Of those,40.3% (95%CI:33.8-46.7%) received TAVR.Of the high-risk
patients,5.2% were candidates.Projections showed that there are approx. 189,836
(95%CI:80,281-347,372) TAVR candidates in the European countries and 102,558
(95%CI:43,612-187,002)in North America. Annually, there are 17,712 (95%CI:7,590-
32,691) new candidates in the EU and 9,189 (95%CI:3,898-16,682) in North America.Conclusions: With a pooled prevalence of 3.4%, the burden of disease among the
elderly due to severe AS is substantial.Under current indications,approx 290,000
elderly patients with severe AS are TAVR candidates.Nearly 27,000 patients become
eligible for TAVR annually.
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Background: Since commercialization in 2007, the number of transcatheter aortic
valve replacement (TAVR) procedures has grown exponentially. Despite the
encouraging results from randomized controlled trials and registries, there is anecdotal
evidence that the utilization of TAVR varies markedly across Europe. We sought to
examine the adoption of TAVR in Western Europe.
Methods: The adoption of TAVR was investigated in 11 European countries:
Germany, France, Italy, United Kingdom, Spain, Netherlands, Switzerland, Belgium,
Portugal, Denmark, and Ireland. Data were collected from two sources: (1) lead
physicians submitted nation-speciﬁc registry data; (2) an implantation-based TAVR-
market tracker. Population data were derived from European Union sources. TAVR
penetration in each nation was determined as a measure of actual TAVR use relative to
potential use.
Results: Between 2007 and 2011, 34,317 patients underwent TAVR. Considerable
variation in TAVR utilization existed across nations. Almost half of all implants were
performed in Germany (45.9%), with Italy (14.9%) and France (12.9%) the next most
frequent implanters. Ireland accounted for the smallest proportion of implants (0.4).
There was wide variation in the number of TAVR implants per million of population.
Germany (88.7) and Portugal (6.1) accounted for the highest and lowest number of
implants per million in 2011, respectively (meanstandard deviation: 32.9  24.9).
The number of centers performing TAVR increased 9-fold from 37 in 2007 to 342 in
2011. On average, there were 0.9  0.6 TAVR centers per million of population. TheJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrannual number of TAVR implants performed per center across nations also varied
widely (range:10 - 89). In 2011, we estimate that there were 28,400 living TAVR
recipients and 158,371 potential TAVR candidates in the 11 study nations. The
weighted average TAVR penetration rate was low: 17.9%. Germany (36.2%) and
Portugal (3.4%) had the highest and lowest TAVR penetration rates, respectively.
2012 - 2013 data will be available for presentation at TCT.
Conclusions: Despite the rapid adoption of TAVR in Europe, our ﬁndings indicate
that TAVR adoption varies markedly across Europe and remains greatly underutilized
in most nations.
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Background: Due to its speciﬁc design the selfexpanding 31mm CoreValve pros-
thesis (for annulus diameters between 26 and 29 mm) with its 4 mm landing zone can
be technically challenging. Thus the procedural results with this device might be
different from the ones with the smaller sizes. In addition the radial force of the nitinol
stent frame is larger in the 31mm device than in the smaller device sizes.
Methods: We retrospectively analyzed the procedural results of the 50 (out of over
600) patients in whom we implanted a 31mm selfexpanding CoreValve bioprosthesis
between 2011 and May 2013 and compared them to the 52 consecutive patients
implanted with a 29 mm device within the same period. Procedural results were
analyzed according to the VARC- criteria.
Results: Patients with large annuli and the 31 mm prosthesis had signiﬁcantly higher
rates of postinterventional pacemaker implantations (34% vs 19% ; p¼0.02) despite
similar implantation depths (6.9 mm vs. 6.6 mm ; p¼ns). Although not signiﬁcant,
there was a tendency towards increased rates of postinterventional aortic regurgitation
of more than mild (AR> grade 1)(14% vs.8%; p¼ns). In contrast major vascular
bleeding (2% vs. 2%), 30-day mortality (6% vs. 7.6%) and stroke/TIA (4% vs. 2 %)
were not different between the two groups.
Conclusions: Despite the technical challenges of the small (4 mm) landing zone,
procedural results with the 31mm device were similar to those with the smaller sizes of
the device. However, postinterventional pacemaker rates were signiﬁcantly higher in
the 31mm cohort despite comparable implantation depths, which might be the result of
the speciﬁc design of the device with its increased radial force.
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Background: Recent data demonstrated that transapical (TA) TAVR is associated
with post-procedural cardiac biomarker elevation in all patients (pts). The impact of
such myocardial damage after TA-TAVR remains uncertain.
Methods: Patients from the PARTNER trial (randomized and continued access
cohorts) treated with TA-TAVR who had baseline and 24h cardiac markers measured
(cardiac troponin I [cTnI] and/or creatine kinase-MB [CKMB]) were studied. Pts were
divided into tertiles (T1, T2, T3) based on the difference between the 24h and the
baseline values of each cardiac marker (DcTnI and DCKMB). Clinical and echocar-
diographic outcomes were compared between tertiles.
Results: A total of 339 pts (T1[-5.62 to 4.41 ng/mL])¼113, T2 [4.41 to 8.01 ng/
mL])¼113, T3 (8.10 to 70.13 ng/mL)¼113) were included in the DcTnI analysis,
while 415 pts (T1 [-27 to 9.3 U/L])¼138, T2 [9.4 to 21.6 U/L]¼139, T3 [22.0 to 438
U/L])¼139) were included in the DCKMB analysis. At 30 days, pts in the highest
tertile (T3) of cardiac biomarker elevation, compared with pts in the lowest tertile
(T1), had similar all-cause mortality rate (DcTnI: T3: 7.1% % vs T1: 6.2%, p¼0.7934;
DCKMB: T3: 12.3% vs T1: 6.5%, p¼0.0996) and cardiovascular mortality rate
(DcTnI: T3: 3.6% vs T1: 3.5%, p¼0.9987; DCKMB: T3: 5.9% vs T1: 4.4%,
p¼0.5629). At 1 year, although numerically higher in T3, there remained no signif-
icant difference between tertiles with respect to all-cause mortality (DcTnI: T3: 30.1%
vs T1: 22.7%, p¼0.1849; DCKMB: T3: 29.3% vs T1: 24.8%, p¼0.3704) (ﬁgure 1)
and cardiovascular mortality (DcTnI: T3: 16.8% vs T1: 14.9%, p¼0.7064; DCKMB:
T3: 17.0% vs T1: 16.6%, p¼0.9925). At 1 year, improvement of the New York Heart
Association (NYHA) functional class (DcTnI: p¼0.6599, DCKMB: p¼0.1734) andacts/POSTER/Aortic Valve Disease and Treatment B229
